102 related articles for article (PubMed ID: 2358224)
1. [Prognostic factors in multiple myeloma].
Pick AI; Tamir R; Vana D; Duczyminer-Kahana M; Weiss H; Lurie H; Dawidowich J; Meyerson E; Gelernter I
Harefuah; 1990 Apr; 118(8):437-42. PubMed ID: 2358224
[TBL] [Abstract][Full Text] [Related]
2. Homogeneous immunoglobulins in Ghanaians living in Accra, Ghana.
Oyeyinka GO; Ofei V; Maddy SQ; Duah OA; Akafo SK; Aquaye JK; Dosoo DK
Afr J Med Med Sci; 2004 Dec; 33(4):311-6. PubMed ID: 15977437
[TBL] [Abstract][Full Text] [Related]
3. [Prognostic factors in IgG and micromolecular multiple myeloma. Retrospective analysis of 50 consecutive cases].
Pasqualetti P; Casale R; Colantonio D; Festuccia V; Di Lauro G; Natali G
Minerva Med; 1987 May; 78(9):603-8. PubMed ID: 3587727
[TBL] [Abstract][Full Text] [Related]
4. [Multiple myeloma of bones. Retrospective study of prognostic factors based on a series of 243 patients].
Bataille R; Donadio D; Morlock G; Rosenberg F; Blotman F; Sany J; Simon L; Izarn P; Serre H
Rev Rhum Mal Osteoartic; 1979 Feb; 46(2):77-83. PubMed ID: 432517
[TBL] [Abstract][Full Text] [Related]
5. [BUN, Bence Jones protein, and chromosomal aberrations predict survival in multiple myeloma].
Okada K; Oguchi N; Shinohara K; Tamura N; Ishii K; Noguchi Y; Hayashi S; Yamamoto H; Takeichi M; Fujimoto H; Shirota T; Hayashi T
Rinsho Ketsueki; 1997 Dec; 38(12):1254-62. PubMed ID: 9455144
[TBL] [Abstract][Full Text] [Related]
6. Prognostic significance of the serum phosphorus level and its relationship with other prognostic factors in multiple myeloma.
Umeda M; Okuda S; Izumi H; Nagase D; Fujimoto Y; Sugasawa Y; Arai C; Natori K; Katoh M; Kuraishi Y
Ann Hematol; 2006 Jul; 85(7):469-73. PubMed ID: 16528526
[TBL] [Abstract][Full Text] [Related]
7. [The wide variations of the clinical behavior and prognosis in multiple myeloma].
Kanoh T; Hirashimizu K
Rinsho Ketsueki; 1993 Apr; 34(4):439-43. PubMed ID: 8510330
[TBL] [Abstract][Full Text] [Related]
8. Prognostic factors and staging systems of multiple myeloma:
Tao ZF; Fu WJ; Yuan ZG; Wang DX; Chen YB; Hou J
Chin Med J (Engl); 2007 Oct; 120(19):1655-8. PubMed ID: 17935664
[TBL] [Abstract][Full Text] [Related]
9. [Prognostic factors affecting survival in multiple myeloma].
Tornóczky J; Tóth A; Sziládi E; Hoffmann E; Liszátz M
Orv Hetil; 1990 Aug; 131(31):1679-84. PubMed ID: 2205822
[TBL] [Abstract][Full Text] [Related]
10. Multiple myeloma index: verification of a new prognostic approach with evaluation of treatment response.
Bettini R; Tonolini M; Bernasconi M
Haematologica; 1998 Aug; 83(8):708-13. PubMed ID: 9793254
[TBL] [Abstract][Full Text] [Related]
11. A review of the cytokine network in multiple myeloma: diagnostic, prognostic, and therapeutic implications.
Lauta VM
Cancer; 2003 May; 97(10):2440-52. PubMed ID: 12733143
[TBL] [Abstract][Full Text] [Related]
12. Hypoalbuminemia in patients with multiple myeloma.
Chen YH; Magalhaes MC
Arch Intern Med; 1990 Mar; 150(3):605-10. PubMed ID: 2310279
[TBL] [Abstract][Full Text] [Related]
13. Prognostic significance of plasma cell propidium iodide and annexin-V indices and their mutual ratio in multiple myeloma.
Scudla V; Ordeltova M; Minarik J; Dusek L; Zemanova M; Bacovsky J
Neoplasma; 2006; 53(3):213-8. PubMed ID: 16652190
[TBL] [Abstract][Full Text] [Related]
14. Age 40 years and under does not confer superior prognosis in patients with multiple myeloma undergoing upfront autologous stem cell transmplant.
Cheema PK; Zadeh S; Kukreti V; Reece D; Chen C; Trudel S; Mikhael J
Biol Blood Marrow Transplant; 2009 Jun; 15(6):686-93. PubMed ID: 19450753
[TBL] [Abstract][Full Text] [Related]
15. Simple prognostic model for patients with multiple myeloma: a single-center study in Japan.
Kaneko M; Kanda Y; Oshima K; Nannya Y; Suguro M; Yamamoto R; Chizuka A; Hamaki T; Matsuyama T; Takezako N; Miwa A; Togawa A
Ann Hematol; 2002 Jan; 81(1):33-6. PubMed ID: 11807633
[TBL] [Abstract][Full Text] [Related]
16. Abnormal cytogenetics predict poor survival after high-dose therapy and autologous blood cell transplantation in multiple myeloma.
Rajkumar S; Fonseca R; Lacy M; Witzig T; Lust J; Greipp P; Therneau T; Kyle R; Litzow M; Gertz M
Bone Marrow Transplant; 1999 Sep; 24(5):497-503. PubMed ID: 10482933
[TBL] [Abstract][Full Text] [Related]
17. [Prognostic factors in multiple myeloma. Selection using multivariate analysis].
Pasqualetti P; Colantonio D; Casale R; Lorenzetti G; Natali G
Recenti Prog Med; 1989 Oct; 80(10):543-6. PubMed ID: 2602637
[TBL] [Abstract][Full Text] [Related]
18. Prognostic factors affecting the survival of patients with multiple myeloma. A retrospective analysis of 86 patients.
Rapoport BL; Falkson HC; Falkson G
S Afr Med J; 1991 Jan; 79(2):65-7. PubMed ID: 1989088
[TBL] [Abstract][Full Text] [Related]
19. Comparison of new patients with Bence-Jones, IgG and IgA myeloma receiving sequential therapy: the need to regard these immunologic subtypes as separate disease entities with specific prognostic criteria.
Sirohi B; Powles R; Kulkarni S; Rudin C; Saso R; Lal R; Singhal S; Mehta J; Horton C; Treleaven J
Bone Marrow Transplant; 2001 Jul; 28(1):29-37. PubMed ID: 11498741
[TBL] [Abstract][Full Text] [Related]
20. Bortezomib plus melphalan and prednisone in elderly untreated patients with multiple myeloma: updated time-to-events results and prognostic factors for time to progression.
Mateos MV; Hernández JM; Hernández MT; Gutiérrez NC; Palomera L; Fuertes M; Garcia-Sanchez P; Lahuerta JJ; de la Rubia J; Terol MJ; Sureda A; Bargay J; Ribas P; Alegre A; de Arriba F; Oriol A; Carrera D; García-Laraña J; García-Sanz R; Bladé J; Prósper F; Mateo G; Esseltine DL; van de Velde H; San Miguel JF
Haematologica; 2008 Apr; 93(4):560-5. PubMed ID: 18322252
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]